| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
To examine the possibility of rapid evaluation about treatment effects of molecular targeted agents by positron emission tomography, the accumulation of 2-deoxy-2[18F]fluoro-D-glucose (FDG) on tumors treated by the anti-neovazcular agent, Bevacizumab, was measured, using COLO205 that was human xenograft transplanted into nude mice. Although Bevacizmab suppressed the growth of tumors, the accumulation of FDG on tumors was increased. It was thought that new tracers should be developed to evaluate the efficacy of each molecular targeted agent.
|
